[Study progress on molecular marker-assisted breeding of Chinese medicinal materials].

The molecular marker-assisted breeding is one of the important methods to cultivate excellent germplasms of Chinese medicinal materials by combining modern molecular biology with traditional genetic breeding. The main target of breeding is to make the biological characters of Chinese medicinal materials stable and the yield and medicinal component of it controllable, and ensure that the medicinal materials produced have the characteristics of "excellent shape, high quality and high effect". Compared with traditional breeding that prefers to the selection of phenotypic traits, the molecular marker-assisted breeding also emphasizes genotype screening. It mainly includes five fields, namely the construction of genetic linkage maps, the positioning of quantitative trait locus(QTL), the analysis of genetic diversities, the identification of varieties and hybrid germplasm purity, and the application of molecular marker-assisted selection. At present, SCoT, ISSR, SSR and SNP are the main DNA markers used in the studies of marker-assisted breeding of Chinese medicinal materials. With the rapid development of high-throughput sequencing technology, genome-wide association(GWAS) and molecular design breeding will become the hotspots of Chinese medicinal materials breeding in the future. In this paper, we review current studies excellent germplasm selection of Chinese medicinal materials using molecular marker-assisted breeding and future development prospects. It is suggested to accelerate the breeding of traditional Chinese medicinal materials using molecular pharmacognosy theory and methods, in order to provide theoretical guidance for breeding, protection and sustainable utilization of traditional Chinese medicinal materials.

Effect of Chuanhuang No. 1 recipe on renal function and micro-inflammation in phase 3 chronic kidney disease patients / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To observe the effect of Chuanhuang No.1 Recipe (CHR) on renal function and micro-inflammation in phase 3 chronic kidney disease (CKD) patients.</p><p><b>METHODS</b>Totally 60 phase 3 CKD patients were randomly assigned to the treatment group (treated by CHR) and the control group (treated by Losartan Potassium), 30 in each group. All patients received basic treatment. Patients in the treatment group took CHR decoction, 400 mL each time, one dose per day, while those in the control group took Losartan Potassium, 50-100 mg per day. All medication lasted for 24 weeks. Changes of serum creatinine (SCr), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), serum uric acid (UA), 24 h urinary protein excretion (24 h U-pro), urinary microalbumin (U-Alb), high-sensitivity C-reactive protein (hs-CRP), serum tumor necrosis factor (TNF)-alpha, and serum IL-6 were detected and compared before and after treatment. Efficacy was also compared.</p><p><b>RESULTS</b>Compared with before treatment, SCr and BUN significantly decreased in the treatment group (P<0.05, P<0.01); eGFR in- creased (P<0.05). Only UA obviously decreased in the control group (P<0.05), but with no obvious change in SCr, BUN, or eGFR. Compared with before treatment, 24 h U-pro decreased after treatment in the treatment group (P<0.05), but with less decreased level when compared with the control group. U- Alb was also significantly decreased in the control group (P<0.01). There was statistical difference in 24 h U-pro and U-Alb between the two groups after treatment (P<0.05). Compared with before treatment, hs-CRP obviously decreased after treatment in the two groups, but serum levels of TNF-alpha and IL-6 obviously decreased only in the treatment group (P<0.05). The total effective rate was obviously higher in the treatment group than in the control group (70.00% vs. 43.33%, P<0.01).</p><p><b>CONCLUSION</b>CHR could efficiently improve the renal function of phase 3 CKD patients and alleviate the micro-inflammation.</p>